untargeted whole genome sequencing - Evaluation and correction of GC biases in cell-free DNA at the fragment level
These are aligned paired-end reads from Illumina NovaSeq 6000 whole-genome sequencing of 4 cfDNA samples extracted from blood plasma (plasma-Seq). Three samples from patients with breast cancer, prostate cancer, or colorectal cancer and one sample from a healthy individual were aligned to GRCh38 (GCA_000001405.15_GRCh38_no_alt_plus_hs38d1_analysis_set). The observed GC bias is different in each of these cfDNA samples which leads to different average GC content per sample. This bias is corrected using the GCparagon commandline tool.
- 2 samples
- DAC: EGAC00001002239
- Technology: Illumina NovaSeq 6000
- RU DUO:0000014 (version: 2019-01-07)research use onlyThis data use limitation indicates that use is limited to research purposes (e.g., does not include its use in clinical care).
- PS DUO:0000027 (version: 2019-01-07)project specific restrictionThis data use modifier indicates that use is limited to use within an approved project.
Liquid Biopsy Policy
European Genome-Phenome Archive c/o European Bioinformatics Institute Wellcome Trust Genome Campus Hinxton Cambridge CB10 1SD United Kingdom To whom it may concern, This document refers to the studies, conducted from the Liquid Biopsy group at the D&R Institute of Human Genetics (Medical University of Graz, Austria) which have been submitted to the European Genome Archive (EGA) for the restricted access by legitimate academic institutions that have agreed to comply with the terms of a Data Access Agreement drafted by Ellen Heitzer. There are a number of steps that a researcher must take to obtain access to this data and the process is overseen by Ellen Heitzer Ellen Heitzer is a Postdoctoral Fellow and is authorized to approve researchers to have encrypted access to the data submitted to the EGA. Please be advised that Ellen Heitzer (ellen.heitzer@medunigraz.at) is authorized to upload data to the EGA for archiving and distribution as part of your submission process, which will enable approved researchers to have encrypted access to the data. We can confirm that this submission is consistent with the informed consent of the participants of the study or has been granted ethical approval and is in accordance with the applicable laws and regulations.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |